NextFin News - Inotiv Inc., a prominent provider of non-clinical drug discovery and development services, filed for Chapter 11 bankruptcy protection on Wednesday, June 3, 2026. The filing in the U.S. Bankruptcy Court for the Southern District of Texas marks a critical turning point for the company, which has struggled with a heavy debt load and regulatory headwinds related to its laboratory animal breeding operations. The company entered the process with a Restructuring Support Agreement (RSA) backed by a majority of its secured lenders, aiming to eliminate approximately $326 million in debt from its balance sheet.
To maintain operations during the court-supervised reorganization, Inotiv secured commitments for $25 million in debtor-in-possession (DIP) financing. This liquidity injection is intended to ensure that the breeding and research facilities continue to function without disruption to client projects. The bankruptcy follows months of visible financial strain; in late May, the company was forced to negotiate a grace period extension for a missed interest payment on its 3.25% Convertible Senior Notes due 2027. While a $40 million bridge loan facility was established earlier this year to provide a temporary buffer, it proved insufficient to stave off a full restructuring.
The company’s downfall is partly attributed to the high costs of integrating past acquisitions and a shifting regulatory landscape for animal testing. Inotiv became a major player in the "non-human primate" supply chain through its acquisition of Envigo in 2021, but that deal brought significant legal and reputational baggage. Federal investigations into the sourcing of monkeys from Cambodia and animal welfare concerns at domestic facilities created a volatile environment that spooked investors and increased compliance costs. According to MarketScreener, the voluntary petition for reorganization is the culmination of these compounding pressures.
Robert Leasure Jr., CEO of Inotiv, characterized the filing as a necessary step to "strengthen the capital structure" and position the company for long-term viability. Under the proposed plan, the massive debt reduction will likely result in existing equity holders being significantly diluted or wiped out, as is common in Chapter 11 cases where secured creditors take control of the reorganized entity. The board also recently approved an Executive Retention Plan, which includes a $1.2 million lump-sum bonus for Leasure, a move that often draws scrutiny from creditors but is defended by companies as essential for leadership stability during a transition.
While the company expects to emerge from bankruptcy as a leaner operation, the broader contract research organization (CRO) industry is watching closely. Some analysts suggest that Inotiv’s troubles are company-specific, rooted in aggressive M&A and specific regulatory failures. However, a more cautious view persists among some credit researchers who argue that rising interest rates and a cooling biotech funding environment have made the high-leverage models used by mid-sized CROs increasingly fragile. From the current evidence, Inotiv’s path to recovery depends entirely on its ability to satisfy federal regulators while convincing pharmaceutical clients that its supply chain is both ethical and stable.
Explore more exclusive insights at nextfin.ai.
